Introduction
============

Human gallbladder cancer is the most common type of malignant tumor in the biliary system worldwide ([@b1-ol-0-0-7159]). Since gallbladder cancer is insensitive to radiotherapy and chemotherapy and the efficiency of radical excision is between 20 and 40%, and the 5-year survival rate is 5% ([@b2-ol-0-0-7159]). As a result, it is important to identify novel therapeutic strategies.

Tumor initiating cells (TICs) have been hypothesized to be the primary cause of tumorigenesis. This hypothesis posits that tumors exhibit a structure composed of heterogeneous subsets of cells at different stages of development, and that the initiation of a tumor is triggered by a certain subset of cells ([@b3-ol-0-0-7159]). As identified by Bonnet and Dick ([@b4-ol-0-0-7159]), TICs serve stem cell functions, and exhibit the potential for self-renewal, differentiation and tumor formation in leukemia. Previous studies have validated the TIC hypothesis in a number of types of solid tumor ([@b5-ol-0-0-7159]--[@b8-ol-0-0-7159]), and cluster of differentiation (CD)133 has been identified as a surface marker for TICs ([@b9-ol-0-0-7159]--[@b11-ol-0-0-7159]). However, it remains unknown whether CD133^+^ TICs exist in human gallbladder cancer.

Effective isolation and purification of a certain subset of tumor cells is the premise to study TICs. The approaches for isolating TICs include cell sorting by surface markers, isolation of cell colonies, isolation of side populations and screening using aldehyde dehydrogenase ([@b12-ol-0-0-7159]). However, identifying TICs in human gallbladder cancer remains in an exploratory stage, due to the lack of stable methods for cell sorting and the identification of biological characteristics. To perform cell sorting by surface markers, the primary approach for isolating and purifying of TICs include magnetic cell sorting (MACS) and fluorescence activated cell sorting ([@b13-ol-0-0-7159]). Despite progress in studying TICs in human gallbladder cancer, it remains unknown whether TICs exist in human gallbladder cancer, and the biological characteristics of TICs remain to be characterized ([@b14-ol-0-0-7159],[@b15-ol-0-0-7159]). In the preliminary investigations of the present study, the proportion of the CD133^+^ subset was determined in a number of human gallbladder cancer cell lines, and the results revealed that this cell subset was relatively increased in GBC-SD cells ([@b14-ol-0-0-7159]). The aim of the present study was to isolate the CD133^+^ subset from human gallbladder cancer cells using immunomagnetic separation, and identify the efficiency of cell sorting using quantitative and localization analysis. Furthermore, the present study aimed to evaluate the capabilities of the CD133^+^ subset by analyzing colony formation, tumor formation *in vivo*, cell proliferation, resistance to drugs, cell invasion, and the expression levels of stem cell-associated markers. The results of the present study may support the TIC hypothesis, and provide a theoretical basis for chemoresistance and tumor invasion.

The interaction between stromal cell-derived factor 1α (SDF-1α) and its receptor, C-X-C chemokine receptor type 4 (CXCR4), is associated with intercellular signal transduction and cell migration ([@b16-ol-0-0-7159]). A previous study identified that the SDF-1α/CXCR4 axis served key functions in the migration, invasion and metastasis of cells in breast, prostate, lung and pancreatic cancer ([@b17-ol-0-0-7159]). The protein kinase B (Akt) signaling pathway primarily participates in cell growth, cell differentiation, tumor invasion and the expression of cancer-associated genes ([@b18-ol-0-0-7159]). Furthermore, a previous study demonstrated that the SDF-1α/CXCR4 axis may promote cell migration through the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway ([@b19-ol-0-0-7159]). In addition, the present study aimed to clarify whether the SDF-1α/CXCR4 and PI3K/Akt axes participated in the metastasis and invasion of human gallbladder cancer cells, and whether certain signaling pathways exist in TICs in human gallbladder cancer.

Materials and methods
=====================

### Animals

A total of 15 5-week old male nude mice (BCLB/c), with a body weight between 20 and 30 g, were supplied by Shanghai Laboratory Animal Center (certificate no. 2007000544043; Shanghai, China). Mice were raised in a specific-pathogen-free feeding room at a temperature of 22--25°C, 0.03% CO~2~. Mice were exposed to a 12-h light/dark cycle, and food and water was routinely provided. All experiments were performed with approval from the Animal Care and Use Committee of Xinhua Hospital, affiliated with the Medical College of Shanghai Jiao Tong University (Shanghai, China).

### Cell culture and cell sorting with immunomagnetic beads

GBC-SD cells (Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China) were cultured at 37°C in Dulbecco\'s modified Eagle\'s medium (DMEM; Genom Biotech Pvt., Ltd., Bhandup, Mumbai) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 U/ml streptomycin in an astrosphere containing 5% CO~2~ and saturated humidity. Cells were passaged every 2--3 days. GBC-SD cells were selected, resuspended with 300 µl PBS at a density of 1×10^7^ cells/ml and sorted using MiniMACS (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer\'s protocol. Following this, cells were resuspended with serum free DMEM supplemented with 20 ng/ml human epidermal growth factor (EGF) and 10 ng/ml human basic fibroblast growth factor (bFGF) (each purchased from PeproTech, Inc., Rocky Hill, NJ, USA), and divided into two groups (CD133^+^ and CD133^−^ groups). Flow cytometry was used to detect the percentage of CD133^+^ cells in each group, as subsequently described.

### Flow cytometry

GBC-SD cells at the logarithmic growth phase (density, 1×10^5^ cells/ml) were used to determine the proportion of the CD133^+^ subset in each group using flow cytometry. GBC-SD cells were digested with 0.2% ethylene diamine tetraacetic acid-trypsin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), resuspended with 80 µl PBS and adjusted to the density of 1×10^7^/ml. An aliquot of 20 µl FcR blocking reagent (Miltenyi Biotec GmbH) was added at room temperature for 1 h. Subsequently, cells were incubated with 10 µl phycoerythrin (PE-) conjugated anti-CD133 antibody (1:500 dilution; cat no. 130-080-801) or PE-conjugated immunoglobulin G (IgG) (negative control; 1:500 dilution) (both from Miltenyi Biotec GmbH) at 4°C for 10 min in a dark room. Following two washes with PBS, cells were resuspended with 500 µl PBS and subjected to detection by flow cytometry, as described previously ([@b20-ol-0-0-7159],[@b21-ol-0-0-7159]), using Flowlogic (v7; Miltenyi Biotec GmbH).

### Immunofluorescence detection

GBC-SD cells at the logarithmic growth phase were seeded in 24-well plates at a density of 1×10^7^ cells/well, fixed with 4% paraformaldehyde for 20 min at room temperature, blocked with 200 µl 1% bovine serum albumin (Beyotime Institute of Biotechnology, Haimen, China) for 30 min at room temperature, and incubated with mouse anti-human CD133 monoclonal antibody (dilution, 1:11; cat no. 130-050-801; Miltenyi Biotec GmbH) at 4°C overnight. PBS was used as a negative control. Subsequently, fluorescein isothiocyanate-labeled goat anti-mouse secondary antibody (dilution, 1:200; cat no. 115-095-003; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was added at 4°C for 1 h. Cell nuclei were stained with DAPI at 4°C for 1 h. Cells were subsequently observed (9 non-overlapping fields of view) using a Nikon ECLIPSE Ti-S fluorescence microscope (Nikon Corporation, Tokyo, Japan).

### Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR)

Total RNA was extracted from CD133^+^ and CD133^−^ GBC-SD cells using TRIzol reagent (Takara Bio, Inc., Otsu Japan), reverse transcribed into cDNA using RevertAid^™^ First-Strand cDNA Synthesis kit (Sangon Biotech Co., Ltd., Shanghai China) (42°C for 30 min, 99°C for 5 min and 4°C for 5 min), and subjected to PCR using a QuantiTect SYBR Green kit (Bimake, Houston, TX, USA) with the following reaction conditions: 94°C for 3 min followed by 35 cycles of 94°C for 30 sec, between 50 and 57°C for 30 sec, 72°C for 30 sec, and 4°C for 10 min. The primers used were as follows: CXCR4 forward, 5′-ATCATCTTCTTAACTGGCATTGTG−3′ and reverse, 5′-GCTGTAGAGGTTGACTGTGTAG-3′; GAPDH forward, 5′-ACGGATTTGGTCGTATTGGGCG-3′ and reverse, 5′-CTCCTGGAAGATGGTGATGG-3′; ABCG2 forward, 5′-GCGACCTGCCAATTTCAAAT-3′ and reverse, 5′-AGCCAGTTGTAGGCTCATCCA−3′; CD44 forward, 5′-CAAGCAATAGGAATGATGTC-3′ and reverse, 5′-GGTCACTGGGATGAAGGT-3′; EGFR forward, 5′-TAACAAGCTCACGCAGTTGG-3′ and reverse, 5′-GCCCTTCGCACTTCTTACAC-3′; Musashi-1 forward, 5′-TAATTCCTGTCCAGCAGTCTC-3′ and reverse, 5′-GAACCATCCCGTCCTGTATCAT-3′; Nanog forward, 5′-CAGCTGTGTGTACTCAATGATAGATTT-3′ and reverse, 5′-ACACCATTGCTATTCTTCGGCCAGTTG-3′; Sox2 forward, 5′-CAAGATGGCCCAGGAGAACC-3′ and reverse, 5′-GCTGCGAGTAGGACATGCTGTA-3′; Oct-4 forward, 5′-GGCGTTCTCTTTGGAAAGGTGTTC-3′ and reverse, 5′-CAAAGCTCCAGGTTCTCTTG-3′; and CD133 forward, 5′-TTACGGCACTCTTCACCT-3′ and reverse, 5′-TATTCCACAAGCAGCAAA−3′.

The length of the PCR product was 228 base pairs; the annealing temperature for CXCR4 was 53°C and for GAPDH was 55°C. The FusionCapt Advance FX7 (Vilber Lourmat, Marne-la-Vallée, France) was used for semi-quantitative analysis of the PCR product. PCR products were separated by electrophoresis on gels containing 2% agarose and visualized using ethidium bromide. GAPDH (Cell Signaling Technology, Inc., Danvers, MA, USA) was amplified as the control. The mRNA expression level of CXCR4 was evaluated by analyzing the ratio of gray value between CXCR4 and GAPDH, as described previously ([@b20-ol-0-0-7159],[@b21-ol-0-0-7159]).

### Western blot analysis

Western blot analysis was performed as previously described ([@b16-ol-0-0-7159],[@b17-ol-0-0-7159]). GBC-SD cells (1×10^5^) were digested using trypsin, treated with 100 µl lysis buffer (Beyotime Institute of Biotechnology) on ice for 30 min and subjected to centrifugation at 4°C (11,279 × g) for 5 min. Determination of protein concentration was performed by BCA assay. Supernatant (60 µl) was combined with loading buffer (15 µl) and 30 µg protein per lane was separated using 10% SDS-PAGE. Proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane with a transfer apparatus (Bio-Rad Laboratories, Inc.). Subsequently, the PVDF membrane was blocked with 5% non-fat milk powder diluted in TBST at room temperature for 2 h and incubated with the following primary monoclonal antibodies (all diluted to 1:200): Mouse anti-human CD133 (cat no. 130-105-226; Miltenyi Biotec GmbH), rabbit anti-human Snail (cat no. 3879s), rabbit anti-epithelial (E-)cadherin (cat no. 3195s), mouse anti-human neural (N-)cadherin (cat no. 13116s), rabbit anti-human Akt (cat no. 4685s), rabbit anti-human phosphorylated (p-)Akt (cat no. 4060s), rabbit anti-human extracellular signal-regulated kinase (Erk; cat no. 4695s), rabbit anti-human p-Erk (cat no. 4370s) (all from Cell Signaling Technology, Inc.), or rabbit anti-human CXCR4 (cat no. ab124824; Abcam, Cambridge, MA, USA) at 4°C overnight. PVDF membrane was subsequently washed for 10 min with Tris-buffered saline (TBS) and Tween-20 (TBST) 3 times. PVDF membrane was incubated with horseradish peroxidase-labeled goat anti-rabbit or anti-mouse IgG secondary antibodies (dilution, 1:2,000; cat nos. 111-225-144 and 115-685-205, respectively; Jackson ImmunoResearch Laboratories, Inc.) at room temperature for 2 h. Subsequently, the membranes were washed for 10 min with TBST twice and once with TBS for 10 min, and developed using enhanced chemiluminescence (Immobilon Western Chemiluminescent HRP substrate; EMD Millipore, Billerica, MA, USA). Films were scanned using Universal Hood II-S.N.76S/01406 (Bio-Rad Laboratories, Inc.). Semi-quantitative analysis was performed using Quantity One software (version 4.62; Bio-Rad Laboratories, Inc.). All experiments were done in triplicate. Mean values were calculated.

### Comparison of proliferation ability in vitro

Target cells in the CD133^+^ or CD133^−^ group were resuspended in DMEM containing EGF (20 ng/ml) and bFGF 10 ng/ml), seeded in 96-well plates (density, 1×10^4^ cells/well) with a final volume of 100 µl, and cultured at 37°C in an atmosphere containing 5% CO~2~. After 24 h, the proliferative ability of cells in each group was compared following the addition of 10 µl Cell Counting Kit-8 (CCK-8) reagent (Cayman Chemical Company, Ann Arbor, MI, USA) every 24 h for 7 days. Cells were allocated into 1 blank control group and 6 experimental groups, for which the mean was taken. Absorbance was determined at 450 nm using the Model 680 (Bio-Rad Laboratories, Inc.), as previously described ([@b21-ol-0-0-7159]).

### Drug sensitivity analysis

Target cells were resuspended in DMEM containing EGF (20 ng/ml) and bFGF (10 ng/ml), seeded in 96-well plates (density, 1×10^4^ cells/well) with a final volume of 100 µl, and cultured at 37°C in an atmosphere containing 5% CO~2~ for 24 h. Subsequently, 0.1 µg/ml fluorouracil (5-FU) or 0.1 µg/ml gemcitabine was added. After 72 h, 10 µl CCK-8 reagent was added, cells were incubated at 37°C for 2 h and absorbance at 450 nm was determined. The mean values were calculated to compare the proliferation rates. The blank control sample was identical but did not contain cells. Inhibition efficiency was calculated as follows: Absorbance (experimental group)/absorbance (blank group) ([@b21-ol-0-0-7159]).

### Colony formation assay

Single cells were obtained from the CD133^+^ or CD133^−^ groups through limiting dilution, and cells were seeded into 96-well plates and cultured with 100 µl serum-free DMEM supplemented with EGF and bFGF for 24 h at 37°C. Colony formation was observed under an inverted light microscope at ×10 magnification. A total of 50 wells containing a single cell were observed and colony formation efficiency was calculated as follows: Number of wells with colonies/50, as described previously ([@b21-ol-0-0-7159]).

### Signal pathway inhibitors

Cells were incubated with SDF-1α (PeproTech, Inc., Rocky Hill, NJ, USA) or an equivalent volume of vehicle at 25, 50, 100 and 200 ng/ml for 2 h and in 37°C for western blotting and at 100 ng/ml for 2 h for all other experiments. To explore the CXCR4/Akt/CD133 signaling pathway, cells were pre-incubated with 40 µmol/l of the CXCR4 inhibitor AMD3100 (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or PI3K inhibitor LY294002 (Cayman Chemical Company) which inhibit the PI3K/Akt pathway, for 30 min at 37°C.

### Tumor formation assay in nude mice

Unsorted cells and cells from the CD133^+^ and CD133^−^ subsets were seeded into the left armpit of nude mice (density, 1×10^5^ cells/ml), and PBS was injected into the opposite side as the negative control. A total of 5 mice were used in each group. Tumor formation efficiency was calculated as the number of mice with tumor formation. Mice were sacrificed 4 weeks later. Tumors were selected, subjected to hematoxylin eosin staining and immunohistochemical staining for histopathological examination under light magnification at ×20 magnification, as previously described ([@b20-ol-0-0-7159],[@b21-ol-0-0-7159]).

### Transwell invasion assay

Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was diluted with serum free DMEM at a ratio of 1:1. The Transwell plates were from Corning Incorporated (Corning, NY, USA) and the upper chamber was coated with 50 µl diluted Matrigel and incubated at 37°C in a cell incubator until the Matrigel solidified. CD133^+^ and CD133^−^ cells in the logarithmic growth phase were resuspended with serum-free DMEM medium and 100 µl cells were seeded in the upper chamber (density, 1--5×10^5^ cells/well). DMEM medium supplemented with 20% fetal bovine serum was added to the lower chamber of the Transwell insert. Following 24 h of culture at 37°C, Matrigel and the cells on the upper surface of the Transwell chamber were wiped off with a cotton swab. Cells were fixed with 4% paraformaldehyde for 20 min and stained with crystal violet at 4°C for 20 min. Subsequently, an Nikon ECLIPSE Ti-S inverted confocal microscope (Nikon Corporation) was used for observation at high magnification (×200) in 9 independent visual fields. The number of transmembrane cells was counted, and the mean value was calculated as previously described ([@b22-ol-0-0-7159]).

### Statistical analysis

SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. All data were presented as the mean ± standard deviation. One-way analysis of variance was used for comparison between groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Purity of sorted cells

GBC-SD cells were divided into CD133^+^ or CD133^−^ groups using MACS with the CD133 marker. As determined using immunofluorescence, CD133, located in the surface of GBC-SD cells, was expressed at an increased level in the CD133^+^ group compared with that in the CD133^−^ group ([Fig. 1A](#f1-ol-0-0-7159){ref-type="fig"}). Flow cytometry detection indicated that the proportion of the CD133^+^ subset in the CD133^+^ group was significantly increased compared with that in the CD133^−^ group (90.2±2 and 17.4±3%, respectively; P=0.001; [Fig. 1B](#f1-ol-0-0-7159){ref-type="fig"}). Semi-quantitative RT-PCR determined that the relative gray value of CD133 mRNA in the CD133^+^ group was significantly increased compared with that in the CD133^−^ group (0.7734±0.0217 and 0.2146±0.0174, respectively; P=0.001; [Fig. 1C](#f1-ol-0-0-7159){ref-type="fig"}). Data from western blot analysis indicated that the relative gray value of the CD133 protein in the CD133^+^ group was significantly increased compared with that in the CD133^−^ group (0.3689±0.0375 and 0.0345±0.0040, respectively; P=0.003; [Fig. 1D](#f1-ol-0-0-7159){ref-type="fig"}).

### Colony formation and tumor formation assay

CD133^+^ cells were subjected to limiting dilution and seeded into 96-well plates with a single cell in each well. After 5 days of culture, between 2 and 3 cells were observed in each well. After 9 days, cell spheres were identified and, 20 days subsequently, sphere colonies with an oval or round shape were observed. Colony formation efficiency in the CD133^+^ group was significantly increased compared with that that in the CD133^−^ group (36.25±2.99 and 4.5±1.29%, respectively; P=0.006; [Fig. 2A and B](#f2-ol-0-0-7159){ref-type="fig"}). Cells in each group were seeded into the left armpit of nude mice at the density of 1×10^5^ cells/ml. After 5 weeks, tumor formation efficiency in the CD133^+^ group and unsorted group was 100 and 60%, respectively, and no tumor was observed in the CD133^−^ group. The shape of the xenograft tumor was oval or round, and the color of the section was pale. Under a light microscope, the hematoxylin and eosin-stained section of the xenograft tumor revealed atypia and invasive growth, and cells were assembled into crypt-like structures. In addition, irregular mitosis was observed. Cells were abnormally assembled in general. As indicated by immunohistochemistry, granules representing the expression of CD133 were localized in the cell membrane and cytoplasm ([Fig. 2C](#f2-ol-0-0-7159){ref-type="fig"}).

### Cell proliferation and drug resistance assay

Doubling time was used to determine the *in vitro* proliferation ability of CD133^+^ and CD133^−^ cells. On day 1, the absorbance in the CD133^+^ group revealed no significant difference when compared with that in the CD133^−^ group (0.1070±0.0075 and 0.1032±0.0022, respectively; P=0.22). Between days 2 and 7, the absorbance of cells in the CD133^+^ group was significantly increased compared with that in the CD133^−^ group (day 2, 0.1950±0.0214 vs. 0.1190±0.0109, P=0.0047; day 3, 0.2607±0.0435 vs. 01575.±0.0048, P=0.0110; day 4, 0.4122±0.0104 vs. 0.1932±0.0169, P=0.0001; day 5, 0.6265±0.0546 vs. 0.2790±0.0357, P=0.0014; day 6, 0.7335±0.0776 vs. 0.3825±0.0160, P=0.0008; day 7, 0.7982±0.0217 vs. 0.4320±0.0606, P=0.0013, respectively; [Fig. 3A](#f3-ol-0-0-7159){ref-type="fig"}). As determined using a CCK-8 assay, following treatment with 0.1 µg/ml 5-FU, the inhibition rate of cell proliferation in the CD133^−^ group was significantly increased compared with in the CD133^+^ group (0.6435±0.0544 and 0.4620±0.0404, respectively; P=0.005). In addition, treatment with 1 µg/ml gemcitabine resulted in a significantly increased inhibition rate of cell growth in the CD133^−^ group compared with that in the CD133^+^ group (0.7185±0.0301 vs. 0.3895±0.0417, respectively; P\<0.001; [Fig. 3B](#f3-ol-0-0-7159){ref-type="fig"}).

### Cell invasion and epithelial-mesenchymal transition (EMT)

As determined using the Transwell assay, the number of transmembrane cells in the CD133^+^ group was significantly increased compared with that in CD133^−^ group (23.78±8.74 vs. 6.56±3.09, respectively; P=0.0007; [Fig. 4A and B](#f4-ol-0-0-7159){ref-type="fig"}). Subsequently, the expression of EMT-associated proteins was conducted using western blot analysis. The results of the present study revealed that the expression of Snail and N-cadherin in the CD133^+^ group were significantly increased, compared with those in the CD133^−^ group (1.4321±0.0448 vs. 0.3489±0.0162, P=0.006; and 1.5061±0.1650 vs. 0.5539±0.0279; P=0.004, respectively). The expression of E-cadherin in the CD133^+^ group was significantly decreased compared with that in the CD133^−^ group (0.8455±0.0453 vs. 1.7998±0.2114, respectively; P=0.016; [Fig. 4C and D](#f4-ol-0-0-7159){ref-type="fig"}).

### Expression of stem cell-associated genes

The results of the semi-quantitative RT-PCR assay indicated that the gray values of ATP-binding cassette sub-family G member 2 (ABCG2) and CD44 mRNA in the CD133^+^ group were significantly increased compared with those in the CD133^−^ group (0.8774±0.0191 vs. 0.3276±0.0272, P=0.001; and 1.3681±0.0879 vs. 0.7891±0.0385, P=0.005, respectively). The expression of EGF-receptor, Musashi-1, Nanog, sex determining region Y-box 2, and octamer-binding transcription factor-4 mRNA did not significantly differ between the two groups (CD133^+^ group, 0.1541±0.0221, 0.1057±0.0122, 0.1088±0.0562, 0.1266±0.0207 and 0.1424±0.0168, respectively; CD133^−^ group, 0.1252±0.0384, 0.1334±0.0194, 0.1175±0.0188, 0.1275±0.0159, and 0.1411±0.0289, respectively; P=0.241, P=0.070, P=0.364, P=0.462, and P=0.472, respectively; [Fig. 5A and B](#f5-ol-0-0-7159){ref-type="fig"}).

### Regulation of the CXCR4/Akt/CD133 signaling pathway

As determined using western blot analysis, the relative gray value referring to the expression level of proteins CXCR4, p-AKT and CD133 were significantly increased in the CD133^+^ group compared with those in the CD133^−^ group (0.5427±0.0135 vs. 0.2770±0.0378, P=0.001; 0.4207±0.0291 vs. 0.2187±0.0035, P=0.005; and 0.5349±0.069 vs. 0.2906±0.0259, P=0.003, respectively, [Fig. 6A](#f6-ol-0-0-7159){ref-type="fig"}). The expression levels of Akt, p-Erk and Erk revealed no statistically significant differences between the two groups (CD133^+^ group, 0.4098±0.0105, 0.6614±0.0320 and 0.6914±0.040, respectively; CD133^−^ group, 0.3759±0.0323, 0.6608±0.0623 and 0.6627±0.0237, respectively; P=0.104, P=0.493, and P=0.084, respectively; [Fig. 6A](#f6-ol-0-0-7159){ref-type="fig"}).

SDF-1α, an activator of CXCR4, was then introduced into the study. Treatment with SDF-1α for 2 h at different concentrations (25, 50, 100 and 200 ng/ml) resulted in increased protein expression levels of CD133, CXCR4 and p-Akt in GBC-SD cells compared with those in the untreated group ([Fig. 6B](#f6-ol-0-0-7159){ref-type="fig"}). When SDF-1α was used at a concentration of 100 ng/ml, protein expression reached the peak value and the level of expression decreased following treatment with 200 ng/ml SDF-1α. Following treatment with SDF-1α (100 ng/ml), the expression of CD133, CXCR4 and p-Akt in GBC-SD cells was determined at different time points (15, 30 min, 1, 2 and 24 h). Compared with those in the untreated group, the expression level of these proteins increased 30 min following treatment, reached the peak value 2 h following treatment, and began to decrease at 24 h following treatment ([Fig. 6B](#f6-ol-0-0-7159){ref-type="fig"}).

In order to identify the associations between CD133 and CXCR4, the activator and inhibitor of CXCR4 (SDF-1α and AMD3100, respectively) and the inhibitors of PI3K/Akt and mitogen-activated protein kinase/ERK signaling pathways were used to treat the CD133^+^ and CD133^−^ groups. In the CD133^+^ group, SDF-1α treatment induced significantly increased expression of CD133 and CXCR4 mRNA expression. Following treatment, with AMD3100, LY294002, or combined treatment with AMD3100 and SDF-1α, LY294002 and SDF-1α, the expression of CD133 and CXCR4 mRNAs significantly decreased in the CD133^+^ group. Additionally, in the CD133^+^ group, following treatment with PD98059 or combined treatment with PD98059 and SDF-1α, the expression of CD133 and CXCR4 mRNA revealed no significant difference. However, in the CD133^−^ group, following treatment with SDF-1α, AMD3100, LY294002, PD98059, or combined treatment with AMD3100 and SDF-1α, LY294002 and SDF-1α, PD98059 and SDF-1α, no significant difference was observed in the mRNA expression of CD133 and CXCR4 ([Fig. 7A](#f7-ol-0-0-7159){ref-type="fig"}).

The signaling pathway alterations in different groups were determined. In the CD133^+^ group, SDF-1α treatment induced significantly increased protein expression of CXCR4, p-Ak and CD133; however, there was no significant difference determined in the expression of Akt, Erk and p-Erk. AMD3100 treatment or combined treatment with AMD3100 and SDF-1α induced significantly decreased expression of p-Akt and CD133, whereas the expression of Akt, Erk, and p-Erk revealed no significant differences. LY294002 treatment or combined treatment with LY294002 and SDF-1α induced significantly decreased expression of p-Akt and CD133, whereas the expression of CXCR4, Akt, Erk and p-Erk revealed no significant differences. PD98059 treatment or combined treatment with PD98059 and SDF-1α induced significantly decreased expression of p-Akt; however, the expression of CXCR4, Akt, p-Akt, Erk and CD133 revealed no significant differences ([Fig. 7B](#f7-ol-0-0-7159){ref-type="fig"}). In the CD133^−^ group, following treatment with SDF-1α, AMD3100, LY294002, PD98059, or combined treatment with AMD3100 and SDF-1α, LY294002 and SDF-1α, PD98059 and SDF-1α, no significant differences were observed in CXCR4, p-Akt, Akt, Erk, p-Erk and CD133 protein expression ([Fig. 7B](#f7-ol-0-0-7159){ref-type="fig"}). The CXCR4/Akt/CD133 axis may serve an important function in the regulation of colony and tumor formation, cell proliferation and chemoresistance, cell invasion and stemness in human gallbladder cancer.

Discussion
==========

TICs make up a small number of cells that remain in the initiation stage of differentiation ([@b23-ol-0-0-7159]). TICs have the ability of self-renewal, limitless proliferation and multi-directional differentiation; therefore, TICs are a key factor for the initiation of malignant proliferation, invasion, and metastasis of tumor cells. Tumor cells in the stage of terminal differentiation lose the capability of differentiation and tumorigenesis ([@b13-ol-0-0-7159],[@b3-ol-0-0-7159]).

Targeting certain cell surface markers may be a useful approach for screening for TICs. Human CD133 antigen is a 5-transmembrane glycoprotein participating in the formation of the topological structure of the cell membrane. The expression of CD133 is downregulated as cell differentiation progresses; therefore, CD133 has become one of the markers for the isolation and identification of tumor stem cells and/or progenitor cells ([@b24-ol-0-0-7159]). Studies on brain, pancreatic, colon and prostate cancer have validated CD133 as an important marker for TICs ([@b10-ol-0-0-7159]--[@b13-ol-0-0-7159],[@b25-ol-0-0-7159]). Previous studies have attempted to isolate TICs from gallbladder cancer, but the biological characteristics of isolated TICs remain unknown ([@b14-ol-0-0-7159],[@b15-ol-0-0-7159]). In preliminary investigations of the present study, CD133 expression in the human gallbladder cancer cell line GBC-SD was significantly increased compared with that in the human gallbladder cancer cell line SGC996. CD133 expression was located in the cell membrane at an increased level of expression. Therefore, using the human gallbladder cancer cell line GBC-SD, it may be possible to obtain abundant CD133^+^-subset cells for further research into their biological characteristics.

The present study is among the first to sort CD133^+^ human gallbladder cancer cells using MACS. Immunofluorescence and flow cytometry analysis indicated that the purity of CD133^+^ cells in CD133^+^ group was significantly increased compared with that of the CD133^−^ group, and CD133 was primarily located in the cell membrane. In addition, the mRNA and protein expression of CD133 in the CD133^+^ group was significantly increased compared with that in the CD133^−^ group.

Tumor formation and colony formation assays are key methods of analyzing tumorigenesis capability ([@b26-ol-0-0-7159]). In the present study, tumor formation efficiency in the CD133^+^ group was 100%, whereas no tumors were observed in the CD133^−^ group. Colony formation in the CD133^+^ group was significantly increased compared with that of the CD133^−^ group. The results of the present study indicated that CD133^+^ cells have tumorigenesis capabilities, and may contain an increased number of TICs than CD133^−^ cells. Furthermore, following treatment with EGF and bFGF for 3 weeks, a single CD133^+^ cell was able to proliferate, forming dozens of cells which made up a cell sphere. Thus, a single CD133^+^ cell, isolated using cell sorting, exhibited self-renewal and colony formation abilities, as do stem cells originated from the same clone.

Limitless proliferation and resistance to drugs are the fundamental characteristics which distinguish TICs from other tumor cells ([@b26-ol-0-0-7159],[@b27-ol-0-0-7159]). The results of the present study indicated that, when cultured with serum free medium supplemented with EGF and bFGF, cells in the CD133^+^ group revealed significantly increased *in vitro* proliferative abilities compared with those in the CD133^−^ group. Gemcitabine and 5-FU are routine chemotherapeutics in clinical use. Sorted cells in the CD133^+^ and CD133^−^ groups were treated with 5-FU and gemcitabine, and drug susceptibility of the cells in the two groups was observed. The inhibiting rate of cell growth in the CD133^−^ group was significantly increased compared with that in the CD133^+^ group, indicating that CD133^+^ cells exhibited decreased sensitivity to anti-tumor drugs.

EMT is a process where epithelial cells lose polarity and transform into mesenchymal cells, followed by subsequent cell migration. EMT is an important characteristic in embryonic development ([@b28-ol-0-0-7159]). A previous study identified that the initiation of EMT served a key function in triggering invasion and metastasis of tumor cells ([@b29-ol-0-0-7159]). In the present study, using an Transwell assay, cells in the CD133^+^ group demonstrated significantly increased invasive abilities compared with those in the CD133^−^ group. Furthermore, protein expression of E-cadherin, a biomarker for epithelial cells, was decreased in the CD133^+^ subset, whereas the protein expression of N-cadherin and Snail, biomarkers for mesenchymal cells, was increased. Therefore, it may be inferred that the increased invasive ability of the CD133^+^ subset was obtained through the initiation of EMT.

A previous study on embryonic stem cells (ESCs) demonstrated that the transcription factors Sox-2, Oct-4 and Nanog form a key regulatory loop that controls the transcription of various mRNAs, and induces the reverse transformation of adult cells into ESCs ([@b30-ol-0-0-7159]). Adenosine triphosphate-binding cassette transporters (ABCs) are transmembrane pumps which transport endogenous lipids, peptides, nucleotides and mycins. The DNA dye Hoechst 33342 may be pumped out of cells by ABCG2, which is used to isolate side population cells exhibiting the characteristics similar to TICs ([@b31-ol-0-0-7159]). As reported by Yin *et al* ([@b14-ol-0-0-7159]), the human gallbladder cancer cell line GBC-SD formed spherical colonies under serum-free culture conditions and the stem cell markers Nanog, Oct-4, Sox-2 and ABCG2 were expressed at an increased level in spherical colonies. The Musashi family is an evolutionarily conserved RNA binding protein in neural cells which is selectively expressed in neural stem/progenitor cells ([@b14-ol-0-0-7159]). A previous study demonstrated that Musashi-1 is associated with the degree of malignancy, clinical pathology and prognosis in colorectal cancer ([@b32-ol-0-0-7159]). The EGF receptor (EGFR) is a receptor that serves important functions in cell proliferation and signal transduction, and is abnormally expressed in a number of types of solid tumor ([@b33-ol-0-0-7159]). In human gallbladder cancer cells, increased expression of EGFR may accelerate the process of malignant tumors through transactivation of inducible nitric oxide synthase ([@b34-ol-0-0-7159]). CD44 has been identified as an important marker for TICs ([@b35-ol-0-0-7159]). In the present study, the expression of stem cell markers in CD133^+^ cells were determined using semi-quantitative PCR, which revealed that ABCG2 and CD44 were highly expressed in CD133^+^ cells and indicated that CD44^+^ or CD44^+^ ABCG^+^ cells may exist in the CD133^+^ group. The expression of Nanog, Oct-4, Sox2, Musashi-1 and EGFR revealed no significant differences, and the underlying molecular mechanism of this requires additional study.

Ping *et al* ([@b36-ol-0-0-7159]) demonstrated that the SDF-1/CXCR4 axis may upregulate the expression of CD133 in glioma stem cells through the PI3K/Akt signaling pathway, and promote the formation of blood vessels. The results of the present study identified that the expression of CXCR4/Akt/CD133 signaling pathway proteins in the CD133^+^ group was significantly increased, compared with that in the CD133^−^ group; therefore, it is possible to infer from these data that proteins in the CXCR4/Akt/CD133 signaling pathway were activated in human gallbladder cancer cell line GBC-SD. Furthermore, GBC-SD cells were treated with SDF-1α, and the intracellular expression of CXCR4, p-Akt and CD133 proteins was determined. The protein expression levels of CXCR4, p-Akt and CD133 were identified to be increased in a time-dependent manner. The present study identified that the optimal concentration of SDF-1α was 100 ng/ml, and the optimal duration for SDF-1α treatment was 2 h.

To determine whether the CXCR4/Akt/CD133 signaling pathway was activated, CD133^+^ GBC-SD cells were treated with SDF-1α and AMD3100 (a specific blocker for CXCR4), and the expression of proteins in CXCR4/Akt/CD133 signaling pathway was observed. The results of the present study identified that SDF-1α significantly promoted the expression of CD133 at the mRNA and protein level in CD133^+^ GBC-SD cells, whereas AMD3100 downregulated the expression of CD133 mRNA and protein. However, in CD133^−^ GBC-SD cells, neither SDF-1α nor AMD3100 treatment resulted in a regulatory effect on CD133 expression. Therefore, in CD133^+^ GBC-SD cells, the SDF-1α/CXCR4 axis participated in the regulation of CD133 expression. The underlying molecular mechanism remains unknown.

Following treatment of CD133^+^ GBC-SD cells with SDF-1α or AMD3100, the protein expression level of p-Akt increased or decreased, whereas the expression of total Akt, p-Erk and total Erk did not change, suggesting that the SDF-1α/CXCR4 axis participated in the regulation of the PI3K/Akt signaling pathway. To identify the underlying molecular mechanisms associating the SDF-1α/CXCR4 axis with the regulation of CD133 expression, CD133^+^ GBC-SD cells were treated with LY294002, a specific inhibitor of the Akt signaling pathway, or PD98059, a specific inhibitor of the Erk signaling pathway, and the expression levels of proteins associated with the CXCR4/Akt/CD133 signaling pathway were determined. In CD133^+^ GBC-SD cells treated with LY294002, the expression of Akt protein did not change and the expression level of p-Akt was downregulated, which resulted in downregulated expression of CD133 at the mRNA and protein level. However, PD98059 treatment did not result in altered in CD133 expression. The results from the present study suggested that the SDF-1α/CXCR4 axis may participate in the regulation of CD133 expression in CD133^+^ GBC-SD cells through the Akt signaling pathway, but not the Erk signaling pathway. In CD133^−^ GBC-SD cells, SDF-1α, AMD3100, LY294002 or PD98059 treatment did not result in significant changes to CD133 expression, indicating that the CXCR4/Akt/CD133 signaling pathway may be specifically activated in CD133^+^ GBC-SD cells.

The results of the present study revealed that, in CD133^+^ GBC-SD cells, SDF-1α or AMD3100 may promote or suppress the SDF-1α/CXCR4 axis, resulting in increased or decreased expression of CD133 in GBC-SD cells through the Akt signaling pathway. Inhibition of the Akt signaling pathway may downregulate CD133 expression in human gallbladder cancer cells.

There are a limited number of previous studies isolating CD133^+^ human gallbladder cancer cells using MACS. The present study demonstrated that the CD133^+^ subset in human gallbladder cancer cell line GBC-SD exhibited TIC characteristics, including increased proliferative and invasive abilities, *in vivo* tumor formation and *in vitro* colony formation, and was resistant to anti-tumor drugs. Furthermore, the CXCR4/Akt/CD133 signaling pathway may be activated in CD133^+^ cells from the human gallbladder cancer cell line GBC-SD.
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![CD133 expression in the human gallbladder cancer cell line GBC-SD following cell sorting using immunomagnetic beads. (A) Transmembrane CD133 expression in CD133^+^ and CD133^−^ groups. CD133 was labeled with red fluorescence as indicated by arrows (magnification, ×200). (B) Proportion of the CD133^+^ subset in the CD133^+^ and CD133^−^ groups in GBC-SD cells, determined using flow cytometry. (C) Detection of CD133 mRNA expression using polymerase chain reaction. GADPH was used as the control. (D) Detection of CD133 protein expression using western blot analysis. GADPH was used as the loading control. CD, cluster of differentiation.](ol-14-06-7111-g00){#f1-ol-0-0-7159}

![Colony formation assay and *in vivo* tumor formation assay. (A) Shape of the colony formed by the CD133^+^ subset (magnification, ×10). (B) Colony formation efficiency in CD133^+^ and CD133^−^ groups. (C) Representative images of the xenograft tumors formed by CD133^+^ cells, with representative HE staining and CD133 IHC staining, as observed under an inverted microscope (magnification, ×200). The arrow indicates CD133^+^ cells. CD, cluster of differentiation; H&E, hematoxylin and eosin; IHC, immunohistochemistry.](ol-14-06-7111-g01){#f2-ol-0-0-7159}

![Cell biology characteristics of cells in the CD133^+^ and CD133^−^ groups. (A) Comparison of the proliferative ability between the CD133^+^ and CD133^−^ groups. (B) Inhibiting rate of cell growth in the CD133^+^ and CD133^−^ groups 72 h after treatment with 5-fluorouracil or gemcitabine. CD, cluster of differentiation.](ol-14-06-7111-g02){#f3-ol-0-0-7159}

![Cell invasion and EMT. (A) Number of transmembrane cells in the CD133^+^ and CD133^−^ groups, observed under an inverted microscope (magnification, ×200). (B) Quantitative analysis of the number of invasive cells. (C) Expression of EMT-associated proteins in the CD133^+^ and CD133^−^ groups. (D) Quantitative analysis of mRNA expression of EMT-associated genes in the CD133^+^ and CD133^−^ groups. EMT, epithelial-mesenchymal transition; CD, cluster of differentiation.](ol-14-06-7111-g03){#f4-ol-0-0-7159}

![Expression of stem cell-associated genes. (A) DNA electrophoresis of stem cell-associated genes in the CD133^+^ and CD133^−^ groups, determined using polymerase chain reaction. (B) Quantitative analysis of mRNA expression level of stem cell-associated genes. GADPH was used as the loading control. CD, cluster of differentiation; CXCR4, C-X-C motif chemokine receptor 4; p-, phosphorylated; Akt, protein kinase B; Erk, extracellular signal-regulated kinase; SDF-1α, stromal cell-derived factor 1α.](ol-14-06-7111-g04){#f5-ol-0-0-7159}

![Regulation of the CXCR4/Akt/CD133 signaling pathway. (A) Differences in CXCR4/Akt/CD133 protein expression between the CD133^+^ and CD133^−^ group. (B) Protein expression of CXCR4/Akt/CD133 as induced by treatment with SDF-1α at different concentrations (25, 50, 100, and 200 ng/ml) and for different durations (15, 30 min, 1, 2, and 24 h).](ol-14-06-7111-g05){#f6-ol-0-0-7159}

![(A) CD133 and CXCR4 mRNA expression profiles in the CD133^+^ and CD133^−^ groups following treatment with SDF-1α/AMD3100/LY294002. (B) CXCR4, p-Akt, Akt, p-Erk, Erk, and CD133 protein expression profiles in the CD133^+^ and CD133^−^ groups following treatment with SDF-1α/AMD3100/LY294002. The CXCR4/Akt/CD133 axis and its potential function. CXCR4, C-X-C motif chemokine receptor 4; Akt, protein kinase B; CD, cluster of differentiation; SDF-1α, stromal cell-derived factor 1α; p-, phosphorylated; Erk, extracellular signal-regulated kinase.](ol-14-06-7111-g06){#f7-ol-0-0-7159}
